Last €50.89 EUR
Change Today 0.00 / 0.00%
Volume 0.0
ABBV On Other Exchanges
New York
EN Paris
As of 3:37 AM 09/29/14 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (ABBV) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/29/14 - €50.89
52 Week Low
10/30/13 - €35.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ABBVIE INC (ABBV)

abbvie inc (ABBV) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. It has a strategic collaboration with Infinity Pharmaceuticals, Inc.; and a research and development collaboration with California Life Sciences LLC. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.

25,000 Employees
Last Reported Date: 08/7/14
Founded in 2012

abbvie inc (ABBV) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $790.0K
Executive Vice President of Commercial Operat...
Total Annual Compensation: $710.0K
Executive Vice President of Business Developm...
Total Annual Compensation: $900.0K
Senior Vice President of Human Resources
Total Annual Compensation: $545.0K
Compensation as of Fiscal Year 2013.

abbvie inc (ABBV) Key Developments

AbbVie to Present Data from its Ongoing Phase 1 Through Phase 3 Hepatitis C Clinical Development Programs at The Liver Meeting

AbbVie announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The Liver Meeting(R), the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 7, 2014 - November 11, 2014. Abstracts will be presented highlighting results from AbbVie's investigational treatment combining three direct-acting antivirals (ABT-450/ritonavir, ombitasvir and dasabuvir) with or without ribavirin (RBV) in patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. These abstracts include a Phase 2/3 study in patients co-infected with human immunodeficiency virus type 1 (HIV-1) (TURQUOISE-I) and a Phase 2 study in liver transplant recipients without cirrhosis (CORAL-I). Additionally, Phase 2 data will be presented from investigational studies evaluating the combination of ABT-450/ritonavir and ombitasvir with or without RBV in genotype 4 (GT4) patients (PEARL-I). AbbVie will also be presenting data from its two additional pipeline HCV compounds, ABT-493 and ABT-530.

AbbVie Releases Interim Results from an Ongoing Phase 2 Study of Its Investigational Compound Veliparib in Combination with Chemotherapy

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35% improvement (P-value=0.14) in progression-free survival (PFS) and a 30% improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC). These results, which evaluated veliparib as a potential treatment for metastatic or advanced NSCLC, were presented for the first time at the 2014 Annual Congress of the European Society for Medical Oncology (ESMO), September 26-30 in Madrid, Spain. Phase 2 Combination Trial in Patients with Non-Small Cell Lung Cancer (Abstract 1234): The Phase 2, randomized, double-blind trial was designed to evaluate the efficacy and safety of veliparib in combination with carboplatin and paclitaxel, two chemotherapeutic medicines. Patients in the squamous histology subgroup randomized to the veliparib arm demonstrated a PFS rate of 6.1 months compared to 4.1 months (HR=0.50; P-value=0.06) and an OS rate of 10.3 months compared to 8.4 months (HR= 0.71; P-value=0.22). Median PFS was improved from 4.2 to 5.8 months, and median OS was improved from 9.1 to 11.7 months. Common adverse events (>=20% of patients) for the veliparib-containing arm included alopecia (39%), anemia (31%), neutropenia (36%), nausea (28%) and peripheral neuropathy (24%). Grade 3 and 4 adverse events (>=10% of patients) included neutropenia (23%) and anemia (10%). AbbVie initiated a Phase 3 clinical trial evaluating veliparib in patients with squamous NSCLC earlier in 2014 to confirm the results of this Phase 2 study. Phase 1 Study in Japanese Patients with Non-Small Cell Lung Cancer (Abstract 1213): Also during ESMO, AbbVie presented data from a Phase 1 study evaluating veliparib in combination with carboplatin and paclitaxel in Japanese patients with NSCLC, which was designed to evaluate the preliminary efficacy of the treatment, as well as the recommended Phase 2 dose. The study demonstrated an overall response rate of 54.5 %, with six patients achieving a partial response and four demonstrating stable disease ranging from 40 to 143 days. The study also demonstrated co-administration of carboplatin and paclitaxel had no significant effect on veliparib pharmacokinetics. Common treatment emergent adverse events (>=20% of patients) were leukopenia (100%), neutropenia (100%), anemia (83.3%), thrombocytopenia (75%), increased aspartate aminotransferase (66.7%) and increased alanine aminotransferase (66.7%). Grade 3 or 4 adverse events occurring in more than two patients were neutropenia (12 patients), leukopenia (4 patients), anemia (3 patients) and hyponatremia (2 patients).

AbbVie's HUMIRA (Adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn's Disease

AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA(R) (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough. This FDA approval represents the eighth indication for HUMIRA in the United States and makes it the first and only biologic treatment approved for use in this patient population that can be administered at home. Crohn's disease is a type of inflammatory bowel disease (IBD) which commonly involves the end of the small intestine and the large intestine. Crohn's disease can appear at any age, but it is most often diagnosed in adolescents and young adults between 15 and 35 years of age. Symptoms of pediatric Crohn's disease are similar to those in adults and can include abdominal pain, weight-loss and diarrhea. Additionally, when Crohn's disease is diagnosed in childhood, it may be more extensive than when it is diagnosed in adulthood. Since there is no known cure for Crohn's disease, one of the treatment goals of pediatric Crohn's disease is to induce and maintain clinical remission. HUMIRA works by inhibiting tumor necrosis factor-alpha (TNF-) and can be self-administered after proper injection training is received and with appropriate physician monitoring.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:FP €50.89 EUR 0.00

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $138.03 USD -0.79
AstraZeneca PLC 4,320 GBp -40.50
Bristol-Myers Squibb Co $50.41 USD -0.12
Eli Lilly & Co $64.75 USD -0.33
Novo Nordisk A/S kr280.20 DKK -3.60
View Industry Companies

Industry Analysis


Industry Average

Valuation ABBV Industry Range
Price/Earnings 22.4x
Price/Sales 4.8x
Price/Book 17.6x
Price/Cash Flow 22.1x
TEV/Sales 3.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at